Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Botulinum toxin type A for chronic anal fissure
2017-001216-11Phase 3Active
- Sponsor
- Dra. A. Teresa Calderón Duque
- Start
- Apr 2017
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of botulinum toxin type A in chronic anal fissure (CAF), sponsored by Dra. A. Teresa Calderón Duque. Primary endpoint: Primary: Clinical outcome of chronic anal fissure. Started Apr 2017; status: active.
02
Drugs
botulinum toxin type A
03
Conditions
chronic anal fissure (CAF)
Beyond the preview
Go deeper on 2017-001216-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-001216-11.